Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03672747
Other study ID # 0580-18-FB
Secondary ID RF1MH117032
Status Completed
Phase N/A
First received
Last updated
Start date February 20, 2019
Est. completion date May 31, 2023

Study information

Verified date September 2023
Source University of Nebraska
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine whether transcranial direct current stimulation (tDCS) can be used alter the amplitude of spontaneous neural activity, and thereby modulate cognitive function in healthy adults


Description:

An emerging neurological tool, called transcranial Direct Current Stimulation (tDCS), has recently been shown to safely and effectively enhance cognition in healthy individuals, as well as reduce key symptomatology in disorders such as stroke and depression, with only negligible side effects. tDCS delivers low-amplitude current to the scalp using small electrodes and part of this current passes through the skull and modulates neural activity in the underlying brain region. How this tiny amount of electric current acts to improve cognitive function and reduce symptoms (e.g., motor impairments in stroke patients with a lesion in motor brain areas) is currently unknown, although many investigators across the world are now working on this problem. Magnetoencephalography (MEG) offers a unique view of neural function, as it can delineate changes in active brain regions with excellent temporal resolution (< 1 ms) and high spatial accuracy (2-3 mm). MEG non-invasively measures the magnetic fields that emanate from active neocortical cells. The potential of the MEG technique to precisely monitor the neural effects of tDCS shows extreme promise, but to date the method has been rarely utilized in this area. Under this protocol, Modulation of Spontaneous Cortical Activity by tDCS: BRAIN Initiative I, approximately 124 participants will provide written informed consent, undergo cognitive and behavioral testing and a structural MRI during a single visit, and then return several weeks later (2-4 weeks) to complete a short tDCS session followed by a MEG recording (i.e., after tDCS). Most participants will return for two more visits, each separated by 2-4 weeks, that include a tDCS session followed by a MEG recording (i.e., 4 total visits). The three tDCS-MEG visits will be identical except that the nature of the stimulation (e.g., location, amplitude, direction/polarity) will be different.


Recruitment information / eligibility

Status Completed
Enrollment 133
Est. completion date May 31, 2023
Est. primary completion date October 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 72 Years
Eligibility Inclusion Criteria: - Informed consent obtained from the participant. - Age: 19-35 years of age at enrollment or 55-72 years of age at enrollment. - Gender: males and females included. - Right-handed based on the Edinburgh Handedness Inventory - Cognitive functioning: Intelligent Quotient (IQ) of 85 - 115 on the Wechsler Adult Intelligence Scale-Revised - Ability to complete the questionnaires in English, as not all the neuropsychological tests and questionnaires have been validated in other languages. Exclusion Criteria: - Current use of the following medications: psychotropic medications or other medications with significant CNS effects (e.g., antipsychotics, psychostimulants, anticonvulsants, alpha-agonists, adrenergic blockers, lithium, and sedating antihistamines), or other excluded medication. - Current psychiatric diagnosis based on the Mini-International Neuropsychiatric Interview (MINI) and/or the adult attention-deficit/hyperactivity disorder (ADHD) diagnostic interview. - Current substance abuse or substance dependence at any time. - The presence of a known neurological disorder or any major medical illness or injury impacting neurological/psychiatric function (e.g., diabetes, epilepsy, cerebral palsy, traumatic brain injury, significant environmental/toxic injury, neurodegenerative disorder, past meningitis/encephalitis). - General medical conditions: any major medical conditions that would interfere with involvement in the study or may affect central nervous system (CNS) function as judged by the investigative team. - History of clinically-significant head trauma. - Pregnancy - Any other condition that, in the opinion of the investigator, is a contraindication to participation - The presence of any ferrous metal implant, including orthodontics (e.g., braces), which may interfere with the MEG data acquisition and/or be a MRI safety concern. - Inability to correct visual acuity to 20/20 with corrective lenses (we can correct from +5 to -6 diopters in .5 diopter steps, separately for each eye, with non-magnetic corrective lenses in the laboratory).

Study Design


Related Conditions & MeSH terms

  • How Occipital tDCS Affects Brain Function in Healthy Adults

Intervention

Device:
transcranial direct-current stimulation (tDCS)
20 minutes duration using high-definition system with center-surround configuration

Locations

Country Name City State
United States University of Nebraska Medical Center Omaha Nebraska

Sponsors (2)

Lead Sponsor Collaborator
University of Nebraska National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioral performance on cognitive tests of attention and perceptual processing Do participants perform better in terms of accuracy and/or reaction time following occipital tDCS on behavioral measures (e.g., the Flanker task) of attention function and/or perceptual processing. During the 90 minutes following stimulation
Secondary The power of spontaneous neural activity as quantified by MEG imaging Does spontaneous alpha (9-13 Hz) and/or gamma (45-80 Hz) power, as measured by MEG, get stronger in the occipital cortices following tDCS. During the 90 minutes following stimulation
Secondary The power of oscillatory neural activity as quantified by MEG imaging Does oscillatory alpha and/or gamma neural activity, as measured by MEG, get stronger in the occipital cortices following tDCS. During the 90 minutes following stimulation